Figure 3.
Figure 3. The 7-gene signature can be used as a classifier to select between bortezomib-based therapy and RD in the independent CoMMpass data set. (A) Kaplan-Meier plot showing the PFS of patients who received RD therapy (n = 40) within CoMMpass and who were predicted to benefit (n = 11; broken line) or not (n = 29; solid line) from bortezomib-based therapy by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (B) HRs for disease progression of bortezomib-good vs bortezomib-standard patients who received RD in CoMMpass. Predictions were made by the 7-gene signature, trained in PADIMAC, and followed repeated (n = 100) training/validation splits (signature). The HRs are compared with a null data set of HRs obtained after permutations of the assignments (null). The P value is that of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed and null performances are the same. (C) Kaplan-Meier plot showing the PFS of patients who received bortezomib-based therapy or RD within CoMMpass (n = 187) and who received the correct (n = 68; broken line) or incorrect (n = 119; solid line) therapy predicted by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (D) Kaplan-Meier plot showing the OS of patients who received bortezomib-based therapy or RD within CoMMpass (n = 187) and who received the correct (n = 68; broken line) or incorrect (n = 119; solid line) therapy predicted by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (E) Kaplan-Meier plot showing the OS of patients (n = 276) who received VRD (n = 208; solid line) or who received bortezomib-based therapy or RD within CoMMpass and who received the correct therapy predicted by the 7-gene signature (n = 68; broken line) after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (F) Kaplan-Meier plot showing the OS of patients who received VRD in CoMMpass (n = 208; solid line) and who were predicted to benefit from RD (n = 164; solid line) or from bortezomib-based therapy (n = 44; broken line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis.

The 7-gene signature can be used as a classifier to select between bortezomib-based therapy and RD in the independent CoMMpass data set. (A) Kaplan-Meier plot showing the PFS of patients who received RD therapy (n = 40) within CoMMpass and who were predicted to benefit (n = 11; broken line) or not (n = 29; solid line) from bortezomib-based therapy by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (B) HRs for disease progression of bortezomib-good vs bortezomib-standard patients who received RD in CoMMpass. Predictions were made by the 7-gene signature, trained in PADIMAC, and followed repeated (n = 100) training/validation splits (signature). The HRs are compared with a null data set of HRs obtained after permutations of the assignments (null). The P value is that of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed and null performances are the same. (C) Kaplan-Meier plot showing the PFS of patients who received bortezomib-based therapy or RD within CoMMpass (n = 187) and who received the correct (n = 68; broken line) or incorrect (n = 119; solid line) therapy predicted by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (D) Kaplan-Meier plot showing the OS of patients who received bortezomib-based therapy or RD within CoMMpass (n = 187) and who received the correct (n = 68; broken line) or incorrect (n = 119; solid line) therapy predicted by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (E) Kaplan-Meier plot showing the OS of patients (n = 276) who received VRD (n = 208; solid line) or who received bortezomib-based therapy or RD within CoMMpass and who received the correct therapy predicted by the 7-gene signature (n = 68; broken line) after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (F) Kaplan-Meier plot showing the OS of patients who received VRD in CoMMpass (n = 208; solid line) and who were predicted to benefit from RD (n = 164; solid line) or from bortezomib-based therapy (n = 44; broken line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal